Skip to Content

News Releases

Aug 05 2026
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook. Second Quarter 2026 Highlights Total company Q2 revenue of $33.7 million, which includes
Jul 26 2026
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight’s common stock and inducement restricted stock units (RSUs) covering a total of
Jul 15 2026
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical
Jul 06 2026
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies Collaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery ALISO VIEJO,
Jul 06 2026
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to
May 19 2026
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time.
May 06 2026
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units 20 Light Delivery
Apr 29 2026
RxSight, Inc. to Present at the Bank of America Healthcare Conference
ALISO VIEJO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., today announced plans to participate in the upcoming Bank of America Healthcare Conference. Management is scheduled to participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 p.m. Pacific Time.
Apr 22 2026
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company’s management will discuss the results during a conference call beginning
Apr 08 2026
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light Adjustable Lens ® (LAL ®) implants have been performed since launch, marking a
Displaying 1 - 10 of 15